Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue dips below year-ago levels

Q1 FY2026 cost of revenue of $17K fell 99.7% year over year, behind the +89.7% change in trailing-twelve-month cost of revenue.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025, down 83.0 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -99.7% toward the trailing-twelve-month pace of +89.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17K— QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMMar 2026
$10.68M+89.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.7%——
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Cost of Revenue vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +89.7% is the 2nd highest of 8, against a peer median of -6.4%.
  • Cost of revenue amounts to 18096.6% of revenue for AVTX, versus a peer median of 36.8%.
AVTX Competitors
Cost of Revenue for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$59.51M USD-6.4%-62.5%56.7%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$45.25M USD+0.0%—50.0%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$10.68M USD+89.7%—18096.6%
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.98M USD-86.0%-44.1%23.7%
QTTBQ32 Bio Inc.LTM Mar 2026$362K USD+0.6%-46.8%0.7%
IMUXImmunic, Inc.LTM Mar 2026$33K USD-50.0%——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€0 EUR———
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
ANABAnaptysBio, Inc.LTM Mar 2026-$38.15M USD-122.7%-69.9%16.4%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding AVTX) —-6.4%-54.7%36.8%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.4M18.05M1.92M441K59K
Cost of Revenue1.49M3.43M1.28M(366K)0
Gross Profit3.91M14.62M640K807K59K
Gross Margin72.4%81.0%33.3%183.0%100.0%
Research & Development59.84M31.31M13.78M52.08M50.08M
Selling, General & Admin24.66M20.71M10.3M17.24M22.9M
Operating Expenses86.04M52.06M27.99M69.32M72.98M
Depreciation & Amortization1.66M166K158K169K344K
EBITDA(80.5M)(37.29M)(23.29M)(34.85M)(77.75M)
EBITDA Margin-1491.2%-206.6%-1210.3%-7901.6%-131779.7%
Operating Income(82.13M)(37.44M)(27.35M)(68.51M)(72.93M)
Operating Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Interest Income0003.32M4.35M
Interest Expense2.39M4.17M3.42M00
Other Income / Expenses(2.41M)(4.19M)(4.18M)33.5M(5.17M)
Income Before Tax(84.55M)(41.63M)(31.53M)(35.02M)(78.09M)
Pre-Tax Margin-1566.2%-230.6%-1638.8%-7939.9%-132362.7%
Income Tax Expense(196K)28K14K114K165K
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Net Margin-1563.1%-230.8%-1639.5%-7965.8%-132642.4%
EPS (Basic)(2,330.66)(1,062.65)(113.58)(4.32)(5.84)
EPS (Diluted)(2,330.66)(1,062.65)(113.58)(3.26)(5.84)
Weighted Avg Shares36.19K39.2K277.73K8.13M13.4M
Weighted Avg Shares (Diluted)36.19K39.2K277.73K10.78M13.4M

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.